These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23413040)

  • 1. Potential benefit of dolutegravir once daily: efficacy and safety.
    Fantauzzi A; Turriziani O; Mezzaroma I
    HIV AIDS (Auckl); 2013; 5():29-40. PubMed ID: 23413040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dolutegravir: clinical efficacy and role in HIV therapy.
    Fantauzzi A; Mezzaroma I
    Ther Adv Chronic Dis; 2014 Jul; 5(4):164-77. PubMed ID: 24982751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dolutegravir, an HIV integrase inhibitor for the treatment of HIV infection.
    Temesgen Z; Talwani R; Rizza SA
    Drugs Today (Barc); 2014 Jan; 50(1):7-14. PubMed ID: 24524102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.
    Cottrell ML; Hadzic T; Kashuba AD
    Clin Pharmacokinet; 2013 Nov; 52(11):981-94. PubMed ID: 23824675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
    Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
    Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review.
    Podany AT; Scarsi KK; Pham MM; Fletcher CV
    Clin Pharmacokinet; 2020 Sep; 59(9):1085-1107. PubMed ID: 32462541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.
    Rathbun RC; Lockhart SM; Miller MM; Liedtke MD
    Ann Pharmacother; 2014 Mar; 48(3):395-403. PubMed ID: 24259658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanisms of action, pharmacology and interactions of dolutegravir].
    Ribera E; Podzamczer D
    Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():2-8. PubMed ID: 25858605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
    Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Integrase inhibitors - new challenges for the treatment of HIV-1 infections].
    Stock I
    Med Monatsschr Pharm; 2013 Dec; 36(12):448-59; quiz 461-2. PubMed ID: 24450269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrase inhibitors: a novel class of antiretroviral agents.
    Schafer JJ; Squires KE
    Ann Pharmacother; 2010 Jan; 44(1):145-56. PubMed ID: 20040702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
    Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
    Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
    Shah BM; Schafer JJ; Desimone JA
    Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of dolutegravir in treatment-experienced patients: the SAILING and VIKING trials].
    Moreno S; Berenguer J
    Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():26-30. PubMed ID: 25858609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection.
    Klibanov OM
    Curr Opin Investig Drugs; 2009 Feb; 10(2):190-200. PubMed ID: 19197797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dolutegravir for the treatment of adult patients with HIV-1 infection.
    Wu G; Abraham T; Saad N
    Expert Rev Anti Infect Ther; 2014 May; 12(5):535-44. PubMed ID: 24694091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
    Raffi F; Jaeger H; Quiros-Roldan E; Albrecht H; Belonosova E; Gatell JM; Baril JG; Domingo P; Brennan C; Almond S; Min S;
    Lancet Infect Dis; 2013 Nov; 13(11):927-35. PubMed ID: 24074642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antiretroviral drug pipeline: prospects and implications for future treatment research.
    Flexner C; Saag M
    Curr Opin HIV AIDS; 2013 Nov; 8(6):572-8. PubMed ID: 24100879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Promise of Dolutegravir: A Novel Second Generation Integrase Strand Transfer Inhibitor.
    Singh H; Kaur M; Kakkar AK; Kumar H
    Curr Clin Pharmacol; 2016; 11(2):88-94. PubMed ID: 27157040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral therapy with integrase inhibitors: more options.
    Raffi F; Wainberg MA
    Virologie (Montrouge); 2013 Apr; 17(2):54-60. PubMed ID: 31910534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.